CRMD logo

CorMedix Inc. (CRMD)

$4.66

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CRMD

Market cap

$370645337

EPS

0.73

P/E ratio

3.3

Price to sales

1.24

Dividend yield

--

Beta

1.479987

Price on CRMD

Previous close

$4.84

Today's open

$4.88

Day's range

$4.65 - $5.06

52 week range

$4.65 - $13.02

Profile about CRMD

CEO

Joseph Todisco

Employees

191

Headquarters

Parsippany, NJ

Exchange

NASDAQ Global Market

Shares outstanding

79537626

Issue type

Common Stock

CRMD industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CRMD

CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates

CorMedix beats Q3 estimates, but DefenCath pricing pressure hurts sales. Rezzayo progress and the planned Heron acquisition shape its 2027 outlook.

news source

Zacks Investment Research • Nov 13, 2026

news preview

What CorMedix (CRMD) Said on Its Q3 Earnings Call

CorMedix NASDAQ: CRMD reported lower third-quarter revenue as its DefenCath product entered a new reimbursement period, while management outlined plans to acquire substantially all of Heron Therapeutics' assets and deferred 2027 guidance for the dialysis treatment.

news source

MarketBeat • Nov 12, 2026

news preview

CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript

CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 12, 2026

news preview

Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

‒ Recently announced acquisition of assets of Heron Therapeutics –  ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million ; Adjusted EBITDA of $3.1 million ‒ ‒ Company maintains FY 2026 revenue and narrows Adjusted EBITDA guidance ‒ ‒ Conference call scheduled for today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J.

news source

GlobeNewsWire • Nov 12, 2026

news preview

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates

CorMedix (CRMD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.57 per share a year ago.

news source

Zacks Investment Research • Nov 12, 2026

news preview

CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings

CorMedix NASDAQ: CRMD has agreed to acquire substantially all of Heron Therapeutics' assets, adding four commercial products and a development agreement to its portfolio of medicines used in hospitals and other institutional settings.

news source

MarketBeat • Nov 10, 2026

news preview

CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio

CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.

news source

Zacks Investment Research • Nov 10, 2026

news preview

CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care

Adds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common stock Additional consideration of up to $55 million in earn-out payments to Heron tied to calendar year 2028 ZYNRELEF net sales plus a royalty on net sales of certain products above a sales threshold Transaction expected to be immediately accretive to CorMedix earnings and free cash flow, as well as estimated to generate $45-$60 million in near-term total operating cost synergies CorMedix entered into a new senior secured term loan facility with funds managed by Pharmakon Advisors and will draw $75 million of non-dilutive financing to support the transaction Heron to remain a publicly traded company with its credit facility repaid, a significant position in CorMedix common stock and rights to earn-out and royalty payments Transaction expected to close in the first quarter of 2027, subject to regulatory clearance and approval by Heron stockholders and other customary closing conditions CorMedix to host a conference call and webcast today at 4:30 p.m. Eastern Time PARSIPPANY, N.J.

news source

GlobeNewsWire • Nov 9, 2026

news preview

CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal

CorMedix Therapeutics (NASDAQ:CRMD) on Monday said it will acquire substantially all assets and assume certain liabilities of Heron Therapeutics, Inc. (NASDAQ:HRTX) in an upfront transaction valued at approximately $222.6 million.

news source

Benzinga • Nov 9, 2026

news preview

CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026

PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will host a corporate update conference call at 8:30 a.m. Eastern Standard Time.

news source

GlobeNewsWire • Nov 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in CorMedix Inc.

Open an M1 investment account to buy and sell CorMedix Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CRMD on M1